GenEdit, a gene therapy development company, announced on the 20th that it has successfully raised $35 million (approximately KRW 47.3 billion) in Series B funding. The round was led by DSC Investment, with participation from Woori Venture Partners and Korea Investment Partners.

Earlier this year, GenEdit entered a collaborative research and licensing agreement with Roche Group’s Genentech to develop treatments for autoimmune diseases.

Founded in 2016 in San Francisco, GenEdit is a biotech established by CEO Gunwoo Lee and Senior Vice President Hyomin Park, both of whom earned PhDs in biotechnology from UC Berkeley.

 The founders leveraged their research experience in gene delivery in collaboration with Nobel laureate Jennifer Doudna to build a company focused on precise gene delivery-based therapeutics in Silicon Valley.

From its inception, GenEdit has enjoyed robust support from global investors such as Sequoia Capital, Bow Capital, and DCVC Bio. Pharmaceutical giant Eli Lilly participated in the company’s previous funding rounds, playing a key role in expanding its global partnerships. Domestic venture capital firms, including Woori Venture Partners, Korea Investment Partners, and Daily Partners, also contributed as early investors, driving GenEdit’s rapid growth.

CEO Gunwoo Lee commented, “Our company’s growth owes much to the trust of our investors and global partners. GenEdit is expanding the boundaries of gene therapy with its innovative gene delivery technology, and this funding will accelerate our research into major indications, including immune disorders.”